Mark J. Tarr Sells 44,976 Shares of Encompass Health Co. (NYSE:EHC) Stock

Encompass Health Co. (NYSE:EHC) CEO Mark J. Tarr sold 44,976 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the transaction, the chief executive officer now owns 554,098 shares in the company, valued at $46,139,740.46. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Encompass Health Price Performance

NYSE:EHC opened at $83.42 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. The business’s 50-day simple moving average is $78.80 and its two-hundred day simple moving average is $71.33. The stock has a market cap of $8.35 billion, a PE ratio of 22.55, a P/E/G ratio of 1.30 and a beta of 0.92. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $85.84.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. The business had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm earned $0.88 earnings per share. As a group, analysts forecast that Encompass Health Co. will post 4.1 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were issued a dividend of $0.15 per share. The ex-dividend date was Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.72%. Encompass Health’s dividend payout ratio is presently 16.22%.

Institutional Investors Weigh In On Encompass Health

Institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC bought a new stake in shares of Encompass Health in the fourth quarter worth about $20,210,000. Jackson Creek Investment Advisors LLC increased its holdings in shares of Encompass Health by 364.4% in the fourth quarter. Jackson Creek Investment Advisors LLC now owns 13,910 shares of the company’s stock worth $928,000 after purchasing an additional 10,915 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Encompass Health by 2.3% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company’s stock worth $87,989,000 after purchasing an additional 29,926 shares during the last quarter. Phocas Financial Corp. increased its holdings in shares of Encompass Health by 112.4% in the fourth quarter. Phocas Financial Corp. now owns 99,875 shares of the company’s stock worth $6,664,000 after purchasing an additional 52,847 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Encompass Health by 21.0% in the fourth quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock worth $6,787,000 after purchasing an additional 17,684 shares during the last quarter. 97.25% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Mizuho raised their price target on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada restated an “outperform” rating and issued a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Stephens restated an “overweight” rating and issued a $85.00 price target on shares of Encompass Health in a research note on Tuesday, January 16th. Raymond James reaffirmed a “strong-buy” rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Finally, Truist Financial raised their target price on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $90.29.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.